MMSET Inhibitor
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Myeloma Service
- 23-222
What's the purpose of the trial?
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Accepting patients
Participating Centers
There are 14 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- KTX-1001 is a kind of drug called an MMSET Catalytic Inhibitor. KTX1001 may work by slowing the growth of cancer cells that express the MMSET protein.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.